Oxytocin-0.9% Nacl (oxytocin in 0.9 % sodium chloride)

No dosing information is available for this tab.

As an oxytocic, oxytocin should be given by IV infusion using a controlled-infusion device. Although oxytocin has been given IM, most clinicians believe this route of administration should not be used for augmentation or induction of labor because the effects it produces are unpredictable and difficult to control.

No dosing information is available for this tab.

No dosing information is available for this tab.

Severe hypertension has been reported when oxytocin was given 3-4 hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia. Cyclopropane anesthesia may modify oxytocin's cardiovascular effects, producing less pronounced tachycardia but more severe hypotension than occurs with oxytocin alone; maternal sinus bradycardia with abnormal atrioventricular rhythms has been noted when oxytocin was used concomitantly with cyclopropane anesthesia. Oxytocin reportedly has delayed induction of thiopental (no longer commercially available in the US) anesthesia by producing venous spasm that caused peripheral pooling of thiopental; however, this interaction has not been conclusively established.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

• Malposition or malpresentation of fetus
• Umbilical cord prolapse
• Uterine hypertonic patterns
• Vasa previa

• Cephalopelvic disproportion
• Fetal distress
• Grand multiparity
• Placenta previa
• Polyhydramnios
• Previous cesarean section

• Hypertension
• Multiple pregnancy

There is no enhanced messaging for this drug.

Rare or Very Rare

• Afibrinogenemia
• Allergic dermatitis
• Anaphylaxis
• Cardiac arrhythmia
• Dyspnea
• Hypertension
• Hypotension
• Pelvic hematoma
• Postpartum hemorrhage
• Seizure disorder
• SIADH syndrome
• Skin rash
• Urticaria
• Uterine rupture in pregnancy
• Ventricular premature beats
• Water intoxication

Rare or Very Rare

• Nausea
• Vomiting

No enhanced messaging available.

No enhanced messaging available.

Animal reproduction studies have not been performed with oxytocin; however, the manufacturers state that the drug is not indicated for use during the first or second trimester of pregnancy other than in relation to spontaneous or induced abortion. Based on wide experience with oxytocin and on its chemical and pharmacologic properties, the drug would not be expected to cause fetal abnormalities when used as indicated. Oxytocin can, however, cause nonteratogenic adverse effects. (See Cautions: Adverse Effects.)

Oxytocin may be distributed in small quantities into milk. If oxytocin therapy is required postpartum (e.g., to control severe bleeding), commencement of nursing should be delayed for at least 1 day after the drug has been discontinued.

No enhanced messaging available.